BHST is the ticker symbol for BIOHARVEST SCIENCES INC., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks BHST with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is BHST a good stock to buy?

BHST is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/BHST.

Where does 13F Pro source BHST data?

All BIOHARVEST SCIENCES INC. fundamentals and ownership data come directly from SEC EDGAR. BIOHARVEST SCIENCES INC. files with the SEC under CIK 1723464. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

BIOHARVEST SCIENCES INC.(BHST)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2024-12-31.

BIOHARVEST SCIENCES INC. (BHST) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BHST is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $25.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2024), BIOHARVEST SCIENCES INC. reports quarterly revenue of $25.2M, net income of $-12.9M, an operating margin of -27.8%. Top institutional holders of BHST by reported 13-F value include Alyeska Investment Group, L.P., THOMPSON SIEGEL & WALMSLEY, Evercore Wealth Management, based on the most recent SEC filings. BHST trades on the Nasdaq exchange and files with the SEC under CIK 1723464. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BHST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOHARVEST SCIENCES INC. directly from SEC EDGAR.

Revenue

$25.2M

Net Income

$-12.9M

Free Cash Flow

$-9.5M

Operating Margin

-27.8%

BHST key financials by period

BIOHARVEST SCIENCES INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2024	40-F	$25.2M	$-12.9M	-27.8%
FY 2023	40-F	$12.7M	$-12.6M	-78.6%

Institutions holding BHST

Institutional investors reporting a position in BIOHARVEST SCIENCES INC. on SEC Form 13F.
Institution	Shares	Value	Reported
Alyeska Investment Group, L.P.	581,441	$1.7M	2026-06-30
THOMPSON SIEGEL & WALMSLEY	364,008	$1.0M	2026-06-30
Evercore Wealth Management	216,343	$618.7K	2026-06-30
True North Advisors	187,318	$535.7K	2026-06-30
Magnus Financial Group	90,000	$257.4K	2026-06-30
SUSQUEHANNA INTERNATIONAL GROUP, LLP	63,658	$179.5K	2026-06-30
Silverberg Bernstein Capital Management	57,723	$162.8K	2026-06-30
KING LUTHER CAPITAL MANAGEMENT	40,000	$114.4K	2026-06-30
TD Waterhouse Canada	23,827	$65.5K	2026-06-30
CITADEL ADVISORS	20,652	$58.2K	2026-06-30

SEC EDGAR: CIK 1723464 →

BIOHARVEST SCIENCES INC.

BHST

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $25.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.